[Stomach ulcer healing with enprostil, an orally effective prostaglandin E2 analog: direct comparative study with ranitidine].
In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with ranitidine given to 93 ambulatory patients with benign gastric ulcers. Under 35 micrograms b.i.d. enprostil the ulcer healing rates after 2, 4, 6 and 8 weeks averaged 22% (10/46), 58% (26/45), 80% (35/44) and 86% (37/43). The corresponding values for ranitidine 150 mg b.i.d. were 22% (10/46), 66% (29/44), 84% (38/45) and 89% (41/46). The differences were not statistically significant. Both drugs had a similar influence on the ulcer symptoms and were well tolerated. The findings suggest that enprostil can be given in a twice daily dosage in the treatment of benign gastric ulcers.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D016620:Enprostil; D006801:Humans; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D011899:Ranitidine / Q000627:therapeutic use*; D012907:Smoking; D013276:Stomach Ulcer / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects*
D011459:Prostaglandins E, Synthetic; D011899:Ranitidine; D016620:Enprostil
Ulcus-ventriculi-Abheilung unter Enprostil, einem oral wirksamen Prostaglandin-E2-Analog: Eine direkte Vergleichsstudie mit Ranitidin.